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INTRODUCTION:  Testicular  cancer  has  high  cure  rates,  especially  after  the  adjuvant  use  of  chemotherapy.
Secondary  tumors  may  develop  months  and  years  after  the primary  tumor.  We  aimed  to  report  a  case  of
cutaneous  Ewing’s  sarcoma  at  the  site  of  surgery  3 years  after  BEP  chemotherapy.
PRESENTATION  OF  CASE:  21  year  old  male underwent  radical  orchiectomy  in  2008.  After  one  year  surgical
site  complaints  brought  him  to same  hospital.  A  limited  surgical  resection  was  made.  As  his complaints
continued  he  applied  to our clinic.  We  resected  the  lesion  with  a 5  cm  safety  margin  with  the light of
previous  medical  history.  Pathology  revealed  cutaneous  Ewing’s  sarcoma,  and  patient  received  VACD-IE
chemotherapy.  He  is  free  of recurrence  till now.
DISCUSSION: Chemotherapy  may  cause  secondary  cancer  especially  in  long  term.  In this  case  secondary
tumor  is diagnosed  three  years  after  surgery.  Patient  underwent  therapeutic  surgery  and  received
chemotherapy  (VACD-IE)  for secondary  Ewing’s  sarcoma.  Early  diagnosis  and  deﬁnitive  treatment
provide  recurrence  free  survival  in  the  patient.
CONCLUSION:  Secondary  tumors  can  emerge  months  or  years  after  primary  tumor  therapies,  and  are  not
related  with  the  primary  tumors.  Any  lesion  or sign  should  be  investigated  carefully.  Early  diagnosis  and
correct  treatment  could  prevent  dramatic  results.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Testicular cancer is the most common solid tumor among males
n the second and third decade of life.1 Testicular cancer has one
f the highest cure rates of all cancers: a ﬁve-year survival rate in
xcess of 90 percent overall.2 Treatment options of testis tumor
epend on the stage of cancer, patients’ tolerability, and the expe-
ience of the physician. BEP chemotherapy, consists of bleomycin,
toposide, and cisplatin, is the choice of treatment in metastatic
esticular germ cell tumors. Tumors developed after radiotherapy
r chemotherapy are called secondary tumors. Secondary tumors
re independent of primary tumors, and can arise months and years
fter the primary tumor.3
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We  aimed to report a case with cutaneous Ewing sarcoma at the
site of surgery 3 years after BEP chemotherapy. To our knowledge it
is the ﬁrst case of secondary Ewing’s sarcoma after chemotherapy
of testicular cancer.
2. Presentation of case
21 year old male patient underwent radical orchiectomy for
testicular mass in a state hospital in 2008. The patient had no
previous story of familial testicular cancer and other malignan-
cies. Pathology report revealed mixed germ cell tumor, and patient
received 2 cycles of BEP chemotherapy in the same hospital. The
patient presented a year later with discharge and inﬂammation
at the site of the wound. A limited surgical resection was  per-
formed and pathology revealed atypical cellular differentiation and
foreign body reaction. Patient’s complaints continued after this
operation and referred to our clinic after 12 months in 2011 (Fig. 1).
Laboratory investigations including complete blood count, blood
urea nitrogen, creatinine, alpha feto protein,  human chorionic
gonadotropin, carcinoembryogenic antigen, and lactate dehydro-
genase levels were in normal ranges. Ultrasound reported that the
lesion was limited to skin and subcutaneous tissue. We  resected
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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tFig. 1. The gross appearance of cutaneous lesion at the site of surgery.
he lesion with a 5 cm safety margin with the light of previous
edical history. Pathology revealed cutaneous Ewing sarcoma with
egative margins (Fig. 2). The patient had received vincristine,
ctinomycin D, cyclophosphamide, doxorubicine, ifosphamide and
toposide (VACD-IE) chemotherapy regime and is free of recur-
ence till September 2013.
. Discussion
Secondary tumors can emerge months or years after primary
umor therapies, and are not related with the primary tumors. The
hemotherapeutics used for the primary tumor, inactivate the can-
er cells by disrupting cellular division, and may  also affect normal
ells in many ways.3 Secondary tumors have different characteris-
ics than primary tumors even in the same region. Furthermore
rimary therapy regimes could restrict secondary therapy, and
educe survival.4,5
Travis et al. studied 40,576 testicular cancer patients with at
east one year of survival. They reported 2200 secondary solid
umors in these patients. This study demonstrated the increased
ncidence in secondary tumors such as leukemia and some solid
umors (lung, thyroid, esophagus, stomach, pancreas, colon, rec-
um, kidney, bladder, connective tissue cancers and malignant
esothelioma). They also reported that younger patients at the
ime of diagnosis might experience high risk of secondary tumors
s they get older.6A similar study was conducted in Holland, reported subdiaphra-
matic radiotherapy increases the risk of secondary tumors. The
tudy also demonstrated a 4% increased risk in radiotherapy and
ig. 2. Cutaneous metastasis of Ewing’s sarcoma. The vascular invasion of metastatic
umor cells (arrow) (Hematoxylin and Eosin stain 40×).PEN  ACCESS
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1.5% increased risk in chemotherapy for secondary tumors in 20
years of follow-up.7
Secondary cancers can occur following treatment with
chemotherapy. Cisplatin as an alkylating agent and etoposide as
a Topoisomerase-II inhibitor have been shown to be the cause of
secondary cancers.8 It was also shown that etoposide and cisplatin
had synergistic effects for secondary leukemia when used together
for chemotherapy.9
The standard chemotherapy of Ewing’s sarcoma has been
evolved since the ﬁrst independent reports of Sutow, and
Pinkel.10,11 In 1974 Rosen et al. reported ﬁrst results of radiothe-
rapy with four drug regimen consisting of vincristine, actinomycin
D, cyclophosphamide, and doxorubicin (VACD) leading to long term
survival.12 The Pediatric Oncology Group–Children’s Cancer Group
(POG-CCG) reported a comparative study of VACD versus VACD
plus etoposide and ifosphamide (IE). VACD-IE group achieved a 5
year event-free survival (EFS) rate of 69% versus 54% in the VACD
group.13
Chemotherapy may  cause secondary cancer especially in long
term. In this case secondary tumor is diagnosed three years
after surgery. Patient underwent therapeutic surgery and received
chemotherapy (VACD-IE) for secondary Ewing’s sarcoma. Early
diagnosis and deﬁnitive treatment provide recurrence free survival
in the patient.
4. Conclusion
Secondary tumors may  arise years after chemotherapy. Any
lesion or sign should be investigated carefully. Early diagnosis and
correct treatment could prevent dramatic results.
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